BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive: Alkaloid Homoharringtonine approved for CML treatment by the FDA as well as antihypertensive agent amiloride and its derivatives BS008 were all proved to normalize oncogenic splicing pattern of Bcl-x in cancer cells depending on PP1 activation [154–156].